For the exclusive license and right to distribute and market Malathion lotion, Taro will pay a royalty, which will be to the tune of USD 2-2.5 million said Venkat Jasti, Chairman & CEO, Suven Life Sciences in an interview to CNBC-TV18. This arrangement is effective until April 2028 unless otherwise terminated.
Suven Life Sciences has granted an exclusive license and right to distribute and market its Malathion Lotion in USA, Canada and Mexico to Taro Pharmaceuticals North America, a subsidiary of Taro Pharmaceutical Industries.
Below is the interview of Venkat Jasti, Chairman & CEO of Suven Life with Reema Tendulkar and Sumaira Abidi on CNBC-TV18.
Sumaira: We also understand that Taro will be paying Suven Life Sciences a royalty. Could you tell us what is the percentage of the royalty that will be paid to you?
A: It depends on the sales volume but rough estimate is because it is an old product but a niche one, we expect to get a royalty of USD 2-2.5 million on an annual basis.
Reema: Any other tie-ups or deals which is in the pipeline which could culminate in the next few months?
A: We are working on some of the ideas but it will come may be in the next 9-12 months not before that.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
